Harnessing soft tissue sarcoma with low-dose pazopanib - a matter of blood levels

Area of Science:

• Oncology
• Pharmacology
• Clinical Pharmacy

Background:

• Pazopanib, a tyrosine kinase inhibitor, treats renal cell carcinoma and soft tissue sarcoma.
• Standard pazopanib dosing is 800 mg once daily (QD), despite high inter-patient variability in pharmacokinetics.
• Pharmacokinetic exposure influences both pazopanib efficacy and toxicity.

Observation:

• Patient A, with metastatic leiomyosarcoma, experienced toxicities and high pazopanib trough concentrations (Cmin) on the standard dose.
• Patient B, with metastatic angiosarcoma and Gilbert syndrome, had elevated bilirubin levels requiring dose reduction.
• Both patients maintained adequate pazopanib Cmin despite dose reductions to 200 mg QD or less frequent administration.

Findings:

• Therapeutic drug monitoring (TDM) of pazopanib is valuable in managing dose reductions due to toxicity.
• Adequate pazopanib exposure (Cmin) can be achieved at doses significantly lower than the standard 800 mg QD.
• Personalized dosing guided by TDM may optimize pazopanib therapy.

Implications:

• TDM can help identify patients who may benefit from lower pazopanib doses while maintaining therapeutic efficacy.
• This approach may mitigate toxicity in sensitive patients.
• Implementing TDM for pazopanib could lead to improved patient outcomes and treatment adherence.